Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer

Debra L. Richardson, Shelly M. Seward, Kathleen N. Moore

Research output: Contribution to journalReview article

Abstract

Antibody drug conjugates are novel mechanisms for delivering chemotherapy. They vary based on the targeted antigen, conjugated cytotoxic, and the type of linker used. These differences determine what cells are targeted. There are 2 antibody drug conjugates approved for use in cancer. For epithelial ovarian cancer, more than 15 antibody drug conjugates are under study. Using antibody drug conjugates in epithelial ovarian cancer makes sense. This review discusses promising trial results demonstrating efficacy. Reported toxicities include visual disturbance. There is an absence of significant hematologic toxicity. Overlapping toxicity between standard cytotoxics and antibody drug conjugates includes neuropathy and constitutional symptoms.

Original languageEnglish (US)
Pages (from-to)1057-1071
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume32
Issue number6
DOIs
StatePublished - Dec 2018

Keywords

  • ADC
  • Antibody drug conjugates
  • Clinical trials
  • Gynecologic malignancy
  • Ovarian cancer
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer'. Together they form a unique fingerprint.

  • Cite this